|
|
 Previous Article | Table of Contents | Next Article 
Rapid recovery from cytopenia in hairy cell leukemia after treatment with
2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections
G Juliusson and J Liliemark
Department of Medicine, Huddinge Hospital, Sweden.
Sixteen patients with symptomatic hairy cell leukemia were treated with a
single course of 2-chloro-2'-deoxyadenosine (CdA), 0.7 mg/kg total dose.
Twelve patients achieved complete remission (CR). One patient with a
CD19+/CD5+/CD25- phenotype and one with a pentostatin-treated CD19+/CD25-
variant form had minor responses. Two patients with advanced disease and
poor performance status died early from invasive mycosis. Three patients
recovered from infections caused by cytomegalovirus and by candida. No
patient had infections caused by bacteria or by unknown organisms. The
median time to full recovery from anemia and thrombocytopenia was 6 and 2
weeks from start of therapy, respectively. Patients with infections,
however, recovered at 13 and 5 weeks, respectively. Neutrophil, monocyte,
and lymphocyte counts returned to normal at a median of 5, 5, and 10 weeks,
respectively. Infections developed more frequently in pancytopenic patients
than in those with one or more blood cell count within the normal range (P
less than .01). All patients with one or no previous therapy had a CR,
whereas those with more than one previous regimen had a lower CR rate (P
less than .01). Thus, 1 week of CdA therapy frequently induced CR also in
patients resistant to interferon. Toxicity was limited, and recovery from
cytopenia was faster than what is reported during interferon therapy.
Volume 79,
Issue 4,
pp. 888-894,
02/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J. Kreitman, D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies
J. Clin. Oncol.,
September 20, 2005;
23(27):
6719 - 6729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Chadha, A. W. Rademaker, P. Mendiratta, B. Kim, D. M. Evanchuk, D. Hakimian, L. C. Peterson, and M. S. Tallman
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience
Blood,
July 1, 2005;
106(1):
241 - 246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. von Rohr, S.-F. H. Schmitz, A. Tichelli, U. Hess, D. Piguet, M. Wernli, N. Frickhofen, G. Konwalinka, G. Zulian, M. Ghielmini, et al.
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
Ann. Onc.,
October 1, 2002;
13(10):
1641 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saven, C. Burian, J. Adusumalli, and J. A. Koziol
Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia
Blood,
April 15, 1999;
93(8):
2471 - 2477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saven, C. Burian, J. A. Koziol, and L. D. Piro
Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment
Blood,
September 15, 1998;
92(6):
1918 - 1926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K Morris, J. M Kolesar, and J. G Kuhn
Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine
Journal of Oncology Pharmacy Practice,
June 1, 1997;
3(2):
94 - 109.
[PDF]
|
|
|
|
|
|
|
P. Fidias, B. A. Chabner, and M. L. Grossbard
Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders
Oncologist,
June 1, 1996;
1(3):
125 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Juliusson, S. Vitols, and J. Liliemark
Mechanisms behind hypocholesterolaemia in hairy cell leukaemia
BMJ,
July 1, 1995;
311(6996):
27 - 27.
[Full Text]
|
|
|
|
|
|
|
A. Saven and L. Piro
Newer Purine Analogues for the Treatment of Hairy-Cell Leukemia
N. Engl. J. Med.,
March 10, 1994;
330(10):
691 - 697.
[Full Text]
|
|
|
|
|
